Biocytogen Announces RenLite® Licensing Agreement with Janssen
8.3.2023 16:25:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Historic French Luxury Leather Goods House Moreau Paris Sold to Leading Manufacturer3.8.2026 12:00:00 EEST | Press release
ASTEREN announces that the Paris Commercial Court has approved the acquisition of Moreau Paris, one of France’s most prestigious luxury leather goods houses, by Cardinal Invest, owner of the French luxury manufacturer Groupe Lécuyer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803029803/en/ Paris flagship rue du Faubourg Saint-Honoré (source: Moreau Paris) The transaction concludes a competitive international sale process conducted under the supervision of the Paris Commercial Court and marks the beginning of a new chapter for one of the last independent historic Paris monogram houses. Led by judicial liquidator Pablo Castanon at ASTEREN, with Richard Morgan Advisory as financial advisor, the process launched in early June attracted substantial interest from trade and financial investors worldwide. The Court order signed on 29 July lays the foundations for renewed investment, international expansion and long-term indus
Kioxia to Showcase CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series for AI Workloads3.8.2026 11:22:00 EEST | Press release
Kioxia Corporation, a world leader in memory solutions, today announced that it will exhibit the KIOXIA XL1 series, a Compute Express Link™ (CXL™) compatible memory expansion module, at the Kioxia booth at FMS: the Future of Memory and Storage, taking place August 4 - 6 in Santa Clara, CA. The product features KIOXIA XL-FLASH™, a low-latency and high-performance flash memory technology that enables flash memory, traditionally used for storage applications, to also be utilized as a memory expansion solution. In addition, it is being designed and developed to support the growing volume of memory-intensive AI applications. Evaluation samples are scheduled to be shipped to industry ecosystem collaborators in August 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803920975/en/ CXL™ Compatible Memory Expansion Module KIOXIA XL1 Series In recent years, the growing number of AI workloads has significantly increased memory de
Leading Data Centre Operator CEO Announced for Data Center World Europe Keynote3.8.2026 10:00:00 EEST | Press release
Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, today announces Svein Alte Hagaseth, Founder and CEO, Heim Datacenter will deliver the opening keynote. A recognised industry leader, Svein spent a decade at Green Mountain in several leadership roles, including CEO, scaling the business from regional challenger to global leader. He is now Founder and CEO of Heim Datacenter, a Nordic platform developing scalable, sustainable infrastructure for hyperscale, high-performance computing. Bill Kleyman, Executive Chair, Data Center Programs, Data Center World/CEO and Co-Founder, Apolo will be joining the keynote as moderator. Data Center World Europe takes place 13-14 October 2026 at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It is co-located with the leading global network infrastructure event Network X. Register fo
Energy Impact Partners Expands Nordic Investment Presence, Deepening Partnership with Nysnø Climate Investments3.8.2026 09:02:00 EEST | Press release
Energy Impact Partners LP ("EIP"), a global investment firm with over $5 billion in assets under management, today announced an expanded commitment to the Nordic energy innovation ecosystem, building on its longstanding strategic partnership with Nysnø Climate Investments ("Nysnø"). The expansion reflects EIP's conviction that Norway and the broader Nordic region will be a defining source of next-generation energy companies. It also marks a deepening of the firm's institutional relationship with Nysnø, an investor in EIP's $1.36 billion flagship fund. Together, the two firms aim to strengthen connectivity between Nordic founders and EIP's global network spanning venture capital, private equity, and credit. "Norway is one of the most sophisticated and forward-looking energy markets in the world," said Matthias Dill, CEO & Managing Partner, Europe at EIP. "We believe many of the defining companies of the next energy economy will emerge from ecosystems like Norway, where deep technical ex
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom